|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||121.30 - 130.86|
|52 Week Range||88.17 - 208.86|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||243.38|
Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.
Ladies and gentlemen, thank you for standing by and welcome to the Reata Pharmaceuticals Fourth Quarter Financial and Full Year 2020 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call today on Reata's website at reatapharma.com in the Investors section.
Reata Pharmaceuticals Inc (NASDAQ: RETA) has submitted a marketing application to the FDA for bardoxolone methyl (bardoxolone) to treat chronic kidney disease caused by Alport syndrome. Alport syndrome is a rare, genetic form of kidney disease caused by mutations in the genes encoding type IV collagen, a major structural component of the kidney's glomerular basement membrane. The kidneys of patients with Alport syndrome progressively lose the capacity to filter waste products out of the blood, leading to end-stage kidney disease. In November last year, the company announced positive Phase 3 CARDINAL study results. Data demonstrated that patients treated with bardoxolone experienced a statistically significant improvement in kidney function measured by eGFR at Week 100 and Week 104, compared to patients treated with placebo. Price Action: RETA shares are up 5.4% at $128.81 in market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaFluidigm Gets EUA Nod For Home Sample Collection Kit For Advanta COVID-19 AssayAvadel's US Application In Sleep Disorder Accepted For Review© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.